<DOC>
	<DOCNO>NCT02653014</DOCNO>
	<brief_summary>This multiple ascend dose ( MAD ) study healthy subject subject mild moderate renal impairment evaluate safety , tolerability pharmacokinetics KBP-5074 . Safety/tolerability data Pharmacokinetics ( PK ) /Pharmacodynamics ( PD ) ( plasma aldosterone , serum potassium , UACR Blood Pressure ) relationship explore support selection dose regimen KBP-5074 suitable Phase II/III study .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics KBP-5074 Healthy Subjects Subjects With Renal Impairment</brief_title>
	<detailed_description>This study consist two part : Part 1 open-label , multiple ascend dose ( MAD ) study evaluate safety , tolerability pharmacokinetics KBP-5074 healthy subject . The safety tolerability assess dose level progress next high dose . Part 2 open label , randomize , parallel study assess safety tolerability , effect renal dysfunction pharmacokinetics KBP-5074 , well PK/PD relationship subject mild moderate renal impairment .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Inclusion Criteria Part 1 : Healthy male female subject Are age 18 45 year ( inclusive ) ; Body mass index ( BMI ) 19 30 kg/m2 inclusive body weight less 50 kg . Exclusion Criteria Part 1 : Clinically significant history gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematologic , psychiatric , renal , hepatic , bronchopulmonary , neurologic , immunologic , lipid metabolism disorder , drug hypersensitivity ; Known suspect malignancy ; Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C ( HCV ) antibody ; Positive pregnancy test result . Inclusion Criteria Part 2 : Are age 18 75 year ( inclusive ) ; Mild moderate chronic kidney disease ( define estimate glomerular filtration rate ( eGFR ) &gt; 30 ≤89 mL/min/1.73 m2 , use modification diet renal disease ( MDRD ) formula , &gt; 3 month ; Proteinuria ( define urine albumin creatinine ratio ( UACR ) ≥100 mg/g ≤3,000 mg/g two midmorning urine specimen within month interval ) ; Subjects treat angiotensinconverting enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) Serum potassium≥3.3 mmol/L ≤4.8 mmol/L ; Body mass index ( BMI ) 19 40 kg/m2 inclusive body weight less 50 kg . Exclusion Criteria Part 2 : Severe uncontrolled hypertension ( diastolic &gt; 115 mmHg systolic blood pressure &gt; 180 mmHg ) either Screening visit Study Checkin Visit ; Type I diabetes mellitus poorly control Type 2 diabetes mellitus ( HbA1c &gt; 10 % ) Screening visit ; Prior kidney transplant , anticipate need transplant study participation ; Clinical diagnosis heart failure persistent symptom ( New York Heart Association [ NYHA ] Class II IV ) either Screening visit Study Checkin Visit ; Known suspect contraindication study medication , include history hypersensitivity allergy ACE inhibitor , ARBs , aldosterone antagonist ; Any clinically significant disorder , except condition associate type 2 diabetes mellitus history , investigator opinion could interfere result trial ; Diabetic gastroparesis ; Known bilateral clinically relevant renal artery stenosis ( &gt; 75 % reduction artery diameter ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>